We are inching ever closer to World Vaccine Congress in Barcelona this October, and our start-up zone is still growing! This week we are pleased to continue introducing more organisations that have already booked their place at the event. To see previous introductions head over to our technology section.   

Why be a start-up at the World Vaccine Congress?    

Start-ups whose applications are successful are entitled to several unique benefits, including exhibition wall space, 2 complimentary passes, and marketing materials. For the first time at this event, there is the opportunity to participate in a 5-minute pitch during lunch breaks, an exciting way of introducing yourselves to colleagues and potential partners.     

Our wonderful start-up manager, Isabella Aung, will receive your application and guide you through the process. She is looking forward to hearing more from interested companies, so do get in touch with her here via email (isabella.aung@terrapinn.com) or head straight to the application page here.     

“I am super excited to connect with and welcome even more start-ups to our start-up zone at our Congress this October! It’s going to be our biggest and most exciting start-up zone yet!” 
  • Figorr leverages IOT technology to enhance cold chain supply operations.
  • The team’s products empower businesses with data to monitor and analyse in real time, as well as optimising the storage and transportation of temperature sensitive goods to prevent loss and damage. These data also allow organisations to access insurance coverage, as companies can properly underwrite and validate claims for perishables.
  • A biotech spinout from the University of Southern Denmark.
  • Using BEMAP technology the team develops novel vaccine candidates to target bacterial infections with no current methods of prevention.
  • The antigens are unique in including highly immunogenic site-specific sugar modifications.
  • The first candidate targets E. coli with healthcare associated urinary tract infections as primary infection.
Iaso Therapeutics
  • Iaso has developed a novel self-assembled mutant Qβ (mQβ) bacteriophage capsid protein.
  • The mQβ platform is an exciting new carrier for conjugate vaccines, providing an attractive alternative to current carriers. It is also associated with reduced antibody generation against the carrier while retaining the ability to elicit high levels of anti-antigen IgG antibodies compared to wild type Qβ.
  • In head-to-head comparison studies, mQβ can induce a 3-10-fold higher IgG antibody titer than CRM-197 or keyhole limpet haemocyanin (KLH) respectively.
  • The mQβ carriers are a platform technology suitable for developing various vaccines.
  • Provides bespoke immunology-focused laboratory services and products to deliver high quality data for industrial or academic partners.
  • Services and products include Multiplex ImmunoAssay Analsysis, Flow Cytometry, and whole blood T cell immunity test kits.
  • With an active research and development programme, including the development of novel T cell assays for infectious diseases, autoimmunity, and cancer, the team is keen to accelerate innovation and improve the health and lives of the general public.

If you would like to join your colleagues in this exciting and continuously growing start-up zone, fill out an application here or contact Isabella here: isabella.aung@terrapinn.com    

Stay tuned for more start-up news, and make sure you subscribe to our weekly newsletters!